The global Graft Versus Host Disease Treatment Market sales is expected to reach US$ 5,655.37 million by 2032, with an 8.3% compound annual growth rate (CAGR). Because of the increased use of corticosteroids and combination medications to treat Graft Versus Host Disease in hematopoietic cell transplant (HCT) patients, the market has been gradually growing. The …